ENDRA Life Sciences Inc. Files S-1 Registration Statement

TL;DR

<b>ENDRA Life Sciences Inc. has filed an S-1 registration statement, signaling a potential public offering or significant corporate action.</b>

AI Summary

ENDRA Life Sciences Inc. (NDRA) filed a IPO Registration (S-1) with the SEC on April 19, 2024. ENDRA Life Sciences Inc. filed an S-1 registration statement with the SEC on April 19, 2024. The company is incorporated in Delaware and its principal executive offices are located in Ann Arbor, MI. The filing is for a registration of securities under the Securities Act of 1933. The company was formerly known as Endra Inc., with a name change effective August 5, 2016. The filing indicates ENDRA Life Sciences Inc. is a smaller reporting company and a non-accelerated filer.

Why It Matters

For investors and stakeholders tracking ENDRA Life Sciences Inc., this filing contains several important signals. This S-1 filing is a prerequisite for public offerings, indicating ENDRA Life Sciences Inc. may be seeking to raise capital or expand its shareholder base. As a smaller reporting company and non-accelerated filer, ENDRA Life Sciences Inc. may have different disclosure requirements and investor profiles compared to larger, more established companies.

Risk Assessment

Risk Level: low — ENDRA Life Sciences Inc. shows low risk based on this filing. The filing is an S-1 registration statement, which is a standard procedural document for public offerings and does not inherently contain negative financial or operational information.

Analyst Insight

Monitor for further filings related to this S-1 to understand the specifics of the proposed offering, including the number of shares and intended use of proceeds.

Key Numbers

• 333- — Registration Number (SEC registration number for the filing)
• 260579295 — IRS Number (IRS Employer Identification Number)
• 3845 — SIC Code (Primary Standard Industrial Classification Code)
• 2024-04-19 — Filing Date (Date the S-1 was filed)
• 2016-08-05 — Name Change Date (Date of former company name change)

Key Players & Entities

• ENDRA Life Sciences Inc. (company) — Registrant name
• Securities and Exchange Commission (regulator) — Filing body
• Delaware (company) — State of incorporation
• Ann Arbor, MI (company) — Principal executive offices location
• Endra Inc. (company) — Former company name
• Francois Michelon (person) — Chief Executive Officer
• K&L Gates LLP (company) — Legal counsel
• Ellenoff Grossman & Schole LLP (company) — Legal counsel

FAQ

Industry Context

ENDRA Life Sciences Inc. operates in the electromedical and electrotherapeutic apparatus industry, focusing on medical technologies.

Regulatory Implications

The S-1 filing is made under the Securities Act of 1933, which governs the registration of new securities offerings in the United States.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering, including share price, number of shares, and use of proceeds.
2. Track subsequent SEC filings from ENDRA Life Sciences Inc. for updates on the registration statement's effectiveness and any offering progress.
3. Analyze the company's financial health and business strategy in conjunction with this S-1 filing to assess investment potential.

Year-Over-Year Comparison

This is an initial S-1 filing, so there is no prior filing of this type to compare against for this specific registration.

Key Financial Figures

• $0.0001 — of [] shares of common stock, par value $0.0001 per share ("common stock"), together wi
• $0.2334 — poses of this preliminary prospectus is $0.2334 (equal to the last sale price of our co
• $1 million — sive—a CT system can cost approximately $1 million and an MRI system can cost up to approx
• $3 million — MRI system can cost up to approximately $3 million. In addition, and in contrast to ultras
• $5,000 — ems can cost as little as approximately $5,000 and the price of new cart-based ultraso
• $75,000 — nd systems can range from approximately $75,000 to $200,000. These numbers include both
• $200,000 — can range from approximately $75,000 to $200,000. These numbers include both portable an
• $65,000 — ystem at a price point of approximately $65,000, which we believe could enable clinical
• $2.9 million — compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2023.

Filing Documents

• endra_s1.htm (S-1) — 356KB
• endra_ex11.htm (EX-1.1) — 226KB
• endra_ex42.htm (EX-4.2) — 114KB
• endra_ex43.htm (EX-4.3) — 110KB
• endra_ex44.htm (EX-4.4) — 95KB
• endra_ex45.htm (EX-4.5) — 97KB
• endra_ex46.htm (EX-4.6) — 24KB
• endra_ex231.htm (EX-23.1) — 2KB
• endra_ex107.htm (EX-FILING FEES) — 42KB
• endra_s1img6.jpg (GRAPHIC) — 8KB
• endra_s1img5.jpg (GRAPHIC) — 28KB
• endra_s1img4.jpg (GRAPHIC) — 9KB
• 0001654954-24-004823.txt (&nbsp;) — 1128KB

USE OF PROCEEDS

USE OF PROCEEDS 11

DILUTION

DILUTION 12 DESCRIPTION OF OUR SECURITIES 13

UNDERWRITING

UNDERWRITING 20 LEGAL MATTERS 22 EXPERTS 22 WHERE YOU CAN FIND MORE INFORMATION 22 INCORPORATION BY REFERENCE 23 You should rely only on the information contained in this prospectus. Neither we nor the underwriter has authorized anyone to provide you with different information and, if provided, such information or representations must not be relied upon as having been authorized by us or the underwriter. This prospectus shall not constitute an offer to sell or a solicitation of an offer to buy offered securities in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. You should read this prospectus together with the additional information described below under the heading " Where You Can Find More Information ." We may also provide a prospectus supplement or post-effective amendment to the Registration Statement to add information to, or update or change information contained in, this prospectus. This prospectus does not contain all of the information included in the Registration Statement. For a more complete understanding of the offering of the securities, you should refer to the Registration Statement, including its exhibits. Unless the context indicates otherwise, in this prospectus, the terms "ENDRA," "we," "us," "our," and the "Company" refer to ENDRA Life Sciences Inc., a Delaware corporation, and its subsidiaries. iii Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will

View Full Filing

View this S-1 filing on SEC EDGAR